Edison Issues ADR Research Update on Erytech Pharma

News provided by

Dec 18, 2015, 07:08 ET

LONDON, December 18, 2015 /PRNewswire/ --

The recent €25.4m ($27.7m) private placement provides Erytech with a healthy cash balance, which should allow effective execution on the strategy to advance and accelerate Graspa/Eryasp in the US, to move development into front-line ALL (acute lymphoblastic leukemia) and to continue pursuing new indications. Two-year follow-up ALL data for Graspa were recently presented at ASH, reinforcing its potential as an effective, safe therapy for patients with few options in this indication. Our valuation is increased to $354.2m with the higher cash balance.

(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Our valuation has increased to $354.2m (from $340m) largely owing to incorporation of the recent €25.4m private placement. We have made no major changes to our underlying Graspa/Eryasp forecasts, which continue to assume that Erytech will retain development and commercialization rights in ALL in the US.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: We are an international equity advisory firm. We enable our client companies to achieve their capital market objectives. The team is made up of more than 80 analysts and investment professionals with many decades of experience. Our extensive company knowledge and industry expertise spans 10 business sectors and more than 700 listed companies globally. We give our corporate clients and investors privileged insight into global investment trends. Our distribution capability is key to ensuring a global investor audience can access our investment knowledge. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact:
Dr Philippa Gardner
Edison Investment Research
+44-(0)20-3681-2521

Jonas Peciulis
Edison Investment Research
+44-(0)20-3077-5728

Christian Glennie
Edison Investment Research
+44-(0)20-3077-5727

[email protected]

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:

LinkedIn http://www.linkedin.com/company/edison-investment-research

Twitter http://www.twitter.com/Edison_Inv_Res

YouTube http://www.youtube.com/edisonitv

Google+ https://plus.google.com/105425025202328783163/posts

SOURCE Edison Investment Research